Onkológia 2/2025
Imunotherapy in treatment of metastatic gastric carcinoma
Gastric carcinoma is one of the most common malignancies of the gastrointestinal tract. The biological aggressiveness of this tumor, caused by high genetic heterogeneity, negatively affects effectiveness of treatment, leading to a decreasing efficacy of standard therapeutic approaches. Although chemotherapy remains a mainstain of treatment, its effectiveness is decreasing due to the development of resistance. Immunotherapy began to be used in the treatment of gastric carcinoma in 2015. The use of immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, has shown promising results in improving treatment response and prolonging survival in selected groups of patients. This breakthrough therapeutic approach offers new hope for patients in whom standard chemotherapy does not demonstrate sufficient efficacy.
Keywords: gastric carcinoma, imunotherapy, nivolumab, pembrolizumab, dostarlimab